About us

EB Announces Exclusive Licensing AgreementwithPBI Portugal Unipessoal Lda.,a wholly owned subsidiary of the German group Pharma Bavaria International

EB Receives Notification from CRO Regarding IND Submission to TFDA for Phase I Clinical Trial of ENERGI-F705PD, an Oral Treatment for Parkinson's

EB's proprietary 'METHOD FOR TREATING EPIDERMO-LYSIS BULLOSA'has been granted patent approvalby the Intell ectual Property Office,Minis

Energenesis's Novel Diabetic Foot Ulcer Gel Wins Excellence Award in Innovation Technology at 2024 Taipei Biotech Awards

Australian Patent Granted for "METHODS FORTREATING DIABETIC ULCER" Following PCT National Phase Entry

Thank you for meeting us at 2024 BIO Europe Spring

We welcome you to visit us at 2024 EWMA Conference

Meet us at 2024 BIO International Convention

Orphan Drug Designation Granted to ENERGI-F703EB by the Committee for Orphan Medicinal Products(COMP) of the European Medicines Agency (EMA)

Energenesis Biomedical has jointly signed a technical service contract with National Taiwan University and Yen Ching Ling Industrial Development Found